Cases & Deals

  • Home
  • Practices
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Intellipharmaceutics

Share

Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Intellipharmaceutics

June 2019

Client(s) Purdue Pharma L.P.

Jones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of a Section 505(b)(2) New Drug Application to the FDA seeking approval of an extended-release oxycodone formulation.

Purdue Pharma L.P., et al. v. Intellipharmaceutics International Inc., et al., Nos. 1-17-cv-00392, 1-18-cv-00404 (D. Del.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.